»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ *frJ^ Ws{
W[E3P,XS
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 K3:|Tc(
lhoq3A
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© HI\f>U
1.Antigen presenting cell£¨APC£© 8i;)|z7
2.Activation induced cell death£¨AICD£© ny(GTKoUz
3.Chemokine _/}Hqh
4.Major histocompatibility complex£¨MHC£© BwJ^_:(p~
5.immunotolerance 5!F\h'E
96pk[5lj{?
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© F`0c?)
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ { ^2W>^
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà Bw<zc=%
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ -~\.n
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ H5rPq_R
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã rjL?eTU"s
8b 8\
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© wfDp,T
3w7
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ jefNiEE[
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ *:9 >W$0u
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ =0h|yjnL/
kxm:g)`=[
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ VJN/#
W ""*hJ
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 >;
&s['H
T2DF'f3A
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ /WgPXE B
1.Antigenic determinant ?aFr8i:)M
2.IgSF '7Mep
]
3.MBL;¾¶ &@YFje6Lcm
4.chemokine s>jr1~~3O_
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ -(\1r2
Y
6.TCR-CD3¸´ºÏÎï (;0$i?3\
7.FADD£¨Fas-associated protein with death domain£© j?:`-\w5
8.AIDS D:wnO|
:
9.Tumor rejection antigen 0 kf(g156
10.AICD +
a-wv
l`@0zw+
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ PXw|
L
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© dqqnCXYuW
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ m`hGDp3
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ j4;Du>obQ
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì w
&p~0cA~
q*\NRq
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ C,o:
DH5bpg&T
gUl1
CH&
רҵ¿Î ÃâÒßѧ gaQ[3g
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 0 _Q*E3
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell oZgHSR RL
5. Fc¦Å receptor 6. Cytokine `9/0J-7*
¶þ¡¢ ÎÊ´ðÌâ =0,|/1~
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 Pp,Um(
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ 'X9AG6K1
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ o`idg[l.
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 Qh*)pt]n
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦ÓᣠC
8N%X2R
9I85EcT^4"
S+r^B?a<oM
Z a!
gbt
;AKwx|I$g
>Iuzk1'S
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ $!f!,fw+
/0(%(2jIWl
vm8$:W2 }
רҵ¿Î ÃâÒßѧ vv+km +
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê S_6g~PHsr
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen 9TC)
w|
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin ioxbf6{
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test J96uyS*
9. Hybridoma technic 10.Mitogen oe9lF*$/
11.Dentritic cell 12.Immunoproliferation 1RLym9JN
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ eTT)P
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ 5Q W}nRCZ
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦ÓᣠV C-d0E0
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ eNbpwne
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ Jd_;@(Eg=
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ J? .F\`N)
0]B(a
k=$AhT=e}n
Or8kp/d
~Wei|,w'<
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ gv|"OlB
vQ1 v#Z
2o4^
רҵ¿Î ÃâÒßѧ BEUK}T K4
Ò»¡¢ Ãû´Ê½âÊÍ '1Y\[T*
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï z=g$Exl
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà po7>IQS]
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ /&^W#U$4
¶þ¡¢ ÎÊ´ðÌâ K\u_Ji]k
1¡¢ TÁܰÍϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ !Ms[eB
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁܰÍϸ°ûºÍЧӦÎïÖÊ¡£ <CZgQ\Mt
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆä¹²Í¬Ìص㼰ÓëÁÙ´²µÄ¹ØÏµ¡£ u5+|Su
4¡¢ ºÎνÁܰÍϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ 4CrLkr
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØÏµÍ³£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ ok{!+VCB5
b?T
>/=> B7
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ =5x&8i
[0y$! f4
2oCkG~j
רҵ¿Î ÃâÒßѧ ypdT&5Mqb!
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê JSr$-C
fH
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR 4(
8xjL:
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA ])}]/Qw
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM MTOy8 Im
¶þ¡¢ ÎÊ´ðÌâ y[?-@7i
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌØµã¡£ 6"f}O<M5H
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ &(N+.T5cp
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖÆµÄÒìͬµã¡£ {{yZ@>
o6
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆä¹¦ÄÜ¡£ _iV]_\0W2
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ 0#cy=*E
x[3A+
Ch \&GzQ
w= P9FxB
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ cLVe T
({WyDu&=
^BQrbY
רҵ¿Î ÃâÒßѧ uocHa5J
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê L|@
y&di
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule 0&_UH}10
5. Autogous mixed lymphoyte reaction mtz#}qD66
¶þ¡¢ ÎÊ´ðÌâ XxIHoX&
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ Rp7ntI:
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ 29CINC
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷Óᣠy\dEk:\)
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹ØÏµ£¿ Ig]iT
'R`tLN
|w aIpB(
ivDGZI9
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ l7# yZ*<v
<S?ddp2
PxH72hBS
רҵ¿Î ÃâÒßѧ {:@tQdM:i8
~.;<
Bj
`W/sP\3
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê ?T+q/lt4
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance .`>y@p!
5. Delayed type hypersensitivity ^&y$Wd]6
¶þ¡¢ ÎÊ´ðÌâ 5onm]V]
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ (Jz;W<E
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ S[WG$
3. ¼òÊöHLAÓëҽѧµÄ¹ØÏµ¡£ ?QE,;QtpK
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷Óᣠ@v}/zS
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷ÓᣠvWGwVH/K
u\eEh*<7q
EkziAON
~NW32
O)/
ai0XL}!+
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ W.kM7z>G
itC-4^
0jEL<TgC
רҵ¿Î ÃâÒßѧ _3ZYtmn.
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê B
~OZ2-~
1. hypersensitivity 2. cluster of differentiation o}ZdTf=
3. adhesion molecules 4. supper antigen 5. split tolerance t
. ;LnrY
¶þ¡¢ ÎÊ´ðÌâ D*lKn62
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ 6'Fd GS
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ x)@G;nZ
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ 9Q"'"b*?z
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ (SvWvm
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ t2)rUWg
;n
7/O5M|
'ET~
o,)?!{k}
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ mGK|ihYu
רҵ¿Î ÃâÒßѧ u?}(P_9
Ò»¡¢ Ãû´Ê½âÊÍ f.9SB
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å -[wGX}}
5. GVHR lz?$f4TzA
¶þ¡¢ ÎÊ´ðÌâ *+#8mA(
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷ÓᣠRx}$0c0
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌØµãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ Hhcpp7cr'
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌØµã¡£ MB~=f[cUnd
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ yjF1}SQ
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ H<PtAYFS
q-}Fvel u
UdpF@Q
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ AT2n V
akL
N/MUwx;P
]7Tkkw$
רҵ¿Î ÃâÒßѧ J1C3&t}
Ò»¡¢Ãû´Ê½âÊÍ 0.8 2kl
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å o!kbK#k
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ 5\]Sv]s)R
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ Bu#VMkchJ
11. »ìºÏÁܰÍϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ ;V *l.gr'2
Èý¡¢ ÎÊ´ðÌâ \1D<!k\S
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ H|3:6x
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ U:^PC
x`
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà D
H\0
z[
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ j+
$rj
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ
Rh_np
|}=acc/
UQ?XqgUM
tX_R_]v3
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ywGd> @
\LR~r%(rM
=P't(<
רҵ¿Î ÃâÒßѧ ^c-
Ò»¡¢Ãû´Ê½âÊÍ itBwCIj G
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó JTSlWq4
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁܰÍϸ°ûµÄ±íÃæ±êÖ¾ ,(qRc(Ho
Èý¡¢ ÎÊ´ðÌâ BJ$9vbhZN
1. ¼òÊöTÁܰÍϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ 7puFz4+f
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ oHd FMD@
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ r`W)0oxD
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ RYQ<Zr$!
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ Ugu[|,
uwzvb gup?
l=S 35og
_}lZ,L(w
Q sZx)
bO
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ gd%NkxmW
Ò»¡¢Ãû´Ê½âÊÍ tItX y
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï S%bCyK%p
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó Cn'(<bl
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ [ey:e6,T9
¶þ¡¢ ÎÊ´ðÌâ R;s?$;I
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ nzd2zY>V
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ K0-ypU*P
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ 6t>.[Y"v
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ c`J.Tm[_u
zKw`Md
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ .{ocV#{s
Ò»¡¢ Ãû´Ê½âÊÍ *w^C"^*
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ \Jx04[=
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ R<\
F:9
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© JlH&??
10¡¢ ÒõÐÔÑ¡Ôñ 15%w 8u
¶þ¡¢ ÎÊ´ðÌâ Bc+w+
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 /(u}KMR!f
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ _,p/l&<
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 ozmrw\_}[
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ o)Iff)m$
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. iP
=V8g?L
2)G
%)'
cc,^6[OH@
@G8lr
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ cJ{ Nh;"
iX0i2e
k
JSkLEa~<
רҵ¿Î ÃâÒßѧ 8K.R=
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ &+cEV6vb+
1. Cytokines 2. adhesion molecules 3. graft versus host reaction Lx\8Z=
4. immunologic tolerance 5. Opsonization N*"p|yhd]
Èý¡¢ ÎÊ´ðÌâ g
l^<Q
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷Óᣠn!NS(.o
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ 5~r33L%
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ kw#;w=\>R{
4. ÃâÒßϵͳɱÉ˰Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ b<a4'M
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ % 5m/
!ipR$ dM
W }8'Pf
"Om=N@?
c#|raXGT
x.f]1S7h[
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ /.3}aj;6
2[Z,J%:0
6eT5ktf
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ xC{qV,
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ 8 7BHq)
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê :K-~fA%kt?
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ byLft1
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û X#*JWQO=
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö \!k1a^ZP
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð {_`^R>"\&w
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖÆ±¸ÔÀí¡£ -n=^
U
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ /JHc! D
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃæ¿¹ÔºÍ±íÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© ,{BaePMp
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ L W[9
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ @ o3T
_I)U%?V+
VtnRgdJ
d Vj_8>
`-(|>5wWS
Fx;QU)1l3
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ #
WAZ9,t
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ )2bvQy8K
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ D)j(,vt
]L9s
%]o
Ò»¡¢ Ãû´Ê½âÊÍ cki81bOT
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß YL]Z<%aKt
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò WU
quN
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô K
P Oa|$
¶þ¡¢ÎÊ´ðÌâ aMtsmL?=
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ In18_bc
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì 6^eV"&+@
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì LIcM3
_.
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ GT0Of~?f
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ 4)A#2
H."EUcE{